Zymeworks' Paul Andrew Moore sells 39,741 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Zymeworks Inc. (ZYME) Chief Scientific Officer Paul Andrew Moore exercised options for 25,000 shares on November 13, 2026, at an exercise price of $5.82 per share; his reported option position afterward covered 175,000 shares. He also sold 39,741 shares in three entries at weighted-average prices of $26.14, $26.09 and $26.04 per share. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F4 | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $5.82 | $146K |
| Sale | Common Stock F1 | 7,367 | $26.14 | $193K |
| Sale | Common Stock F2 | 7,374 | $26.09 | $192K |
| Sale | Common Stock F3 | 25,000 | $26.04 | $651K |
Footnotes (4)
- F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.07 to $26.21, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.05 to $26.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.95 to $26.11, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F4. Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
Key Figures
Key Terms
weighted average price financial
equal monthly installments technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the transaction-price ranges for Paul Moore's ZYME sales?
How do Paul Moore's Zymeworks stock options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.